Skip to main content
Premium Trial:

Request an Annual Quote

P&G Pharma, Scuttling Internal Discovery, Will End Some Existing Vendor Contracts

NEW YORK, March 14 (GenomeWeb News) - Procter & Gamble Pharmaceuticals will retain some of its genomic-related alliances and end others after the company late last month decided to shutter its internal drug-discovery program, GenomeWeb News has learned.

 

"We are currently evaluating all of our discovery contracts," P&G spokesperson Tom Milliken said in an email message to GenomeWeb News today. "Some of them will remain open as originally planned, and others will not, depending upon the value that each adds to our new strategy." P&GP spokeswoman Paula Koenigs said the company's new strategy involves moving out of drug discovery and into external licensing agreements and drug acquisitions.

 

P&GP has many R&D collaboration with various genomic-related tool vendors. However, the company could not specify which would be affected by the closure.

 

The shuttered program means lost opportunities for existing collaborators, potential future allies, or past partners, such as Inpharmatica, which  delivered model GPCRs last year to P&GP. The company last week said P&GP's decision closed the door for lead-optimization deals. "We could have expanded," said Vinod Mehta, senior vice president of business development at Inpharmatica. "Those opportunities in lead-optimization were affected."

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.